Synthesis, characterization and anticancer activity of Fe(II) and Fe(III) complexes containing...

A series of Fe(II) complexes (1-4) and Fe(III) complexes (5-8) from Fe(II)/(III) chloride and N-(8-quinolyl)-X-salicylaldimine Schiff base ligands (Hqsal-X₂/X: X = Br, Cl) were successfully synthesized and characterized by spectroscopic (FT-IR, ¹H-NMR), mass spectrometry, thermogravimetric analysis (TGA), and single crystal X-ray crystallographic techniques. The interaction of complexes 1-8 with calf thymus DNA (CT-DNA) was determined by UV-Vis and fluorescence spectroscopy. The complexes exhibited good DNA-binding activity via intercalation. The molecular docking between a selected complex and DNA was also investigated. The in vitro anticancer activity of the Schiff base ligands and their complexes were screened against the A549 human lung adenocarcinoma cell line. The complexes showed anticancer activity toward A549 cancer cells while the free ligands and iron chloride salts showed no inhibitory effects at 100 µM. In this series, complex [Fe(qsal-Cl₂)₂]Cl 6 showed the highest anticancer activity aginst A549 cells (IC₅₀ = 10 µM). This is better than two well-known anticancer agents (Etoposide and Cisplatin). Furthermore, the possible mechanism for complexes 1-8 penetrating A549 cells through intracellular ROS generation was investigated. The complexes containing dihalogen substituents 1, 2, 5, and 6 can increase ROS in A549 cells, leading to DNA or macromolecular damage and cell-death induction.